Health ProductsPublic Communication

For the Public - Possible Association of Remicade (infliximab) with hepatosplenic T-cell lymphoma in pediatric and young adult patients with Crohn's disease

· Published by Health Canada · Official notice

Details

Alert type: Public Communication
Category: Biologic/vaccine, Affects children, pregnant or breast feeding women
Audience: General Public
Department: Health Canada
Get told about the next health product recall.

We email or text you when Canada issues a recall that matches what you watch: a brand, a product, an allergen. Most never make the news.

Get health product recall alerts

CA$3.99/mo · cancel anytime

Details

The Health Products and Food Branch (HPFB) posts on the Health Canada web site safety alerts, public health advisories, press releases and other notices as a service to health professionals, consumers, and other interested parties. These advisories may be prepared with Directorates in the HPFB which includes pre-market and post-market areas as well as market authorization holders and other stakeholders. Although the HPFB grants market authorizations or licenses for therapeutic products, we do not endorse either the product or the company. Any questions regarding product information should be discussed with your health professional.

This is duplicated text of a letter from Schering Canada, Inc.
Contact the company for a copy of any references, attachments or enclosures.

Help on accessing alternative formats, such as Portable Document Format (PDF), Microsoft Word and PowerPoint (PPT) files, can be obtained in the alternate format help section.

(PDF Version - 1012 K)

Contact : MHPD_DPSC

Notice about Health Canada advisories

Public Communication - Health Canada Endorsed Important Safety Information on Remicade (infliximab)

July 27, 2006

Subject: Possible Association of REMICADE® with a rare form of cancer in children and young adults with Crohn's disease

Centocor, Inc. and Schering Canada Inc., in cooperation with Health Canada, have informed health care professionals of important information concerning REMICADE® (infliximab). REMICADE® belongs to a class of products called tumor necrosis factor blockers or TNF-blockers.

REMICADE® has been authorized for use in Canada since 2001, and is used for the treatment of adults with rheumatoid arthritis, Crohn's disease, ankylosing spondylitis, ulcerative colitis, psoriatic arthritis, and chronic plaque psoriasis. Please note the following safety information:

  • REMICADE® is not authorized in Canada for use in children.

  • A rare form of cancer, a lymphoma that affects the liver and spleen, has been reported in children and young adults taking REMICADE® for Crohn's disease.

  • A total of six (6) cases have been reported, with five cases resulting in death. Patients had been receiving REMICADE® for up to 4 years.

  • All patients had also been taking other drugs that suppress the immune system and may increase the risk of cancer. As a result, the role of REMICADE® in causing this cancer is not clear.

This rare cancer is called hepatosplenic T-cell lymphoma. All six cases involving REMICADE® were reported in the United States. In addition, all patients were taking other drugs that suppress the immune system (immunosuppressants), including azathioprine and 6-mercaptopurine. The chronic use of immunosuppressants may increase the risk of certain types of cancer, including lymphoma (see information on the causes of lymphoma at:
http://www.cancer.ca/ccs/internet/standard/0,3182,3172_10175_272682_langId-en,00.html).

REMICADE® is not authorized in Canada for use in children, and there have been no reports of any cancer associated with REMICADE® use in this population in Canada.

Hepatosplenic T-cell lymphoma is an extremely rare cancer, with only 150 cases reported worldwide since the disease was first recognized in the early 1990's. The cancer is aggressive and most patients die within 2 years of diagnosis.

Signs and symptoms of hepatosplenic T-cell lymphoma include the following:

  • Enlarged liver and spleen without enlargement of lymph nodes;

  • Unusual fatigue, fever, chills, night sweats, decreased appetite, and weight loss.

  • Drops in some blood cell counts, which may lead to bruising, paleness, or easy bleeding.

Patients who experience these or any other unusual symptoms should contact their physician immediately.

The prescribing information for REMICADE® will be revised to include this updated information.

This advisory is in addition to the letter issued to health care professionals concerning this information. The letter can be accessed at Health Canada's website via the following link:
http://www.hc-sc.gc.ca/dhp-mps/medeff/advisories-avis/prof/_2006/index-eng.php

Schering Canada is a research-based pharmaceutical company based in Pointe-Claire, Quebec and is a country operation of Schering-Plough Corporation.

For further information call Schering Canada Medical Services at (800) 463 5442 from 8:30 a.m. to 4:30 p.m. Monday to Friday, EST. For media inquiries, call Kent Hovey-Smith, Schering Canada Inc., (514) 428-7475.

Any occurrences of serious and/or unexpected adverse reactions in patients receiving REMICADE® (infliximab) should be reported to Schering Canada, Inc., or Health Canada, at the following addresses:

Schering Canada, Inc.
3535 Trans-Canada Highway
Pointe Claire, Quebec, H9R 1B4
Tel: (800) 463-5442
Fax: (800) 369-3090

Any suspected adverse reaction can also be reported to:
Canadian Adverse Drug Reaction Monitoring Program (CADRMP)
Marketed Health Products Directorate
HEALTH CANADA
Address Locator: 0701C
OTTAWA, Ontario, K1A 0K9
Tel: (613) 957-0337 or Fax: (613) 957-0335
To report an Adverse Reaction, consumers and health professionals may call toll free:
Tel: 866 234-2345
Fax: 866 678-6789
cadrmp@hc-sc.gc.ca

The AR Reporting Form and the AR Guidelines can be found on the Health Canada web site or in The Canadian Compendium of Pharmaceuticals and Specialties.

For other inquiries related to this communication, please contact Health Canada at:
Marketed Health Products Directorate (MHPD)
E-mail: MHPD_DPSC@hc-sc.gc.ca
Tel: (613) 954-6522
Fax: (613) 952-7738

Get told about the next health product recall.
Get health product recall alerts

CA$3.99/mo · cancel anytime